Year: 2025

MALTA, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) — GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2025. Key Third Quarter Financial HighlightsRevenue of $1.688 billion Gross margin of 24.8% and Non-IFRS gross margin(1) of 26.0% Operating margin of 11.6% and Non-IFRS operating margin(1) of 15.4% Net income of $249 million and Non-IFRS net income(1) of $232 million Diluted earnings per share of $0.44 and Non-IFRS diluted earnings per share(1) of $0.41 Non-IFRS adjusted EBITDA(1) of $573 million Ending cash, cash equivalents and marketable securities of $4.2 billion Net cash provided by operating activities of $595 million and Non-IFRS adjusted free cash flow(1) of $451 million“GF delivered a strong third quarter, with revenue, gross margin, operating...

– Reports Revenue of $1.3 Million – Posting third consecutive quarter of growth –– Lowest Quarterly Net Loss in the last Decade – Evidencing further progress toward profitability – SAN JOSE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Energous Corporation d/b/a Energous Wireless Power Solutions (Nasdaq: WATT) (the “Company,” “we,” or “our”), a pioneer in scalable, over-the-air (OTA) wireless power networks, today announced financial results for the third quarter ended September 30, 2025, reporting revenue of approximately $1.3 million for the third quarter, representing a 30% increase versus the second quarter of 2025, and a 38% improvement in net loss in the third quarter compared to the same prior year period. The Company also provided an update on recent events and Company highlights. “We are building the...

Company to Webcast Conference Call Live at 9:00 a.m. ET CANTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men’s clothing and shoes, announced today it will release its third quarter of fiscal 2025 financial results before the market opens on Thursday, December 4, 2025. President and Chief Executive Officer Harvey Kanter and Executive Vice President, Chief Financial Officer, and Treasurer Peter Stratton will host a conference call the same morning at 9:00 a.m. ET to discuss the results. Participants can join by conference call or webcast: Conference Call To participate in the conference call, please pre-register at:https://register-conf.media-server.com/register/BI179eabc9adaa4a199a67a98e41c452cdUpon registering, you will receive a dial-in...

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of the heme program and initiate preclinical development of in vivo-engineered TCR-T for solid tumors Cash, cash equivalents, and marketable securities expected to fund operations into the second half of 2027 WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the third quarter ended...

– Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision – – Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 – – OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease – – Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia – – Strengthened capital position from recent equity offering and non-dilutive funding from patient advocacy groups – RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus...

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson’s Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health authorities to extend the duration of the Phase 1b study, allowing participants to continue treatment with GT-02287 for a total of 12 months; with a majority of subjects electing to participate in the study extension Analysis of functional changes and biomarker activity at 90 days expected to be available during 4Q 2025 BETHESDA, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company...

– Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement –  – Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – – Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations – – Conference call today at 8:00 am ET – DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the third quarter ended September 30, 2025, and provided...

AleAnna, Inc. Reports Positive Net Income, EBITDA, EPS and Cash from Operations in Third Quarter 2025 Third Quarter 2025 Results and Recent Company Highlights:AleAnna generated $5.3 million of net income and $6.3 million of EBITDA(1) in the third quarter driven by strong production at the Longanesi field generating $11.2 million of revenue in the quarter AleAnna reported basic and diluted net income per share of class A common stock of $0.08 for the quarter ended September 30, 2025 AleAnna generated $8.9 million of cash from operations during the third quarter and closed the period with a strong cash position of approximately $31.2 million.DALLAS, Nov. 12, 2025 (GLOBE NEWSWIRE) — AleAnna, Inc. (“AleAnna” or “the Company”) (NASDAQ: ANNA) today announced financial and operational results for the third quarter of 2025. AleAnna...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026   Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported...